<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-1681</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>СИМПТОМАТИЧЕСКИЕ ГИПЕРТОНИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>СИМПТОМАТИЧЕСКИЕ ГИПЕРТОНИИ</subject></subj-group></article-categories><title-group><article-title>Ремоделирование сердца и легочной артерии в зависимости от уровня натрийуретических пептидов и активации ренин-ангиотензин -альдостероновой системы у больных легочной гипертензией различной  этиологии</article-title><trans-title-group xml:lang="en"><trans-title>Heart and pulmonary artery remodeling association with various levels of natriuretic peptides and renin-angiotensin-aldosterone system activation in patients with pulmonary hypertension of various etiology</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Андреева</surname><given-names>Ю. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Andreeva</surname><given-names>Yu. A.</given-names></name></name-alternatives><email xlink:type="simple">gurieva@fromru.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Саидова</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Saidova</surname><given-names>M. A.</given-names></name></name-alternatives><email xlink:type="simple">gurieva@fromru.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мартынюк</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Martynyuk</surname><given-names>T. V.</given-names></name></name-alternatives><email xlink:type="simple">gurieva@fromru.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Масенко</surname><given-names>В. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Masenko</surname><given-names>V. P.</given-names></name></name-alternatives><email xlink:type="simple">gurieva@fromru.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Наконечников</surname><given-names>С. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Nakonechnikov</surname><given-names>S. N.</given-names></name></name-alternatives><email xlink:type="simple">gurieva@fromru.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чазова</surname><given-names>И. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Chazova</surname><given-names>I. E.</given-names></name></name-alternatives><email xlink:type="simple">gurieva@fromru.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГУ Российский кардиологический научно-производственный комплекс Росмедтехнологии, г. Москва</institution></aff><aff xml:lang="en"><institution>Russian Cardiology Scientific and Clinical Complex, Federal Agency on High Medical Technologies. Moscow</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>20</day><month>12</month><year>2008</year></pub-date><volume>7</volume><issue>7</issue><fpage>62</fpage><lpage>68</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Андреева Ю.А., Саидова М.А., Мартынюк Т.В., Масенко В.П., Наконечников С.Н., Чазова И.Е., 2008</copyright-statement><copyright-year>2008</copyright-year><copyright-holder xml:lang="ru">Андреева Ю.А., Саидова М.А., Мартынюк Т.В., Масенко В.П., Наконечников С.Н., Чазова И.Е.</copyright-holder><copyright-holder xml:lang="en">Andreeva Y.A., Saidova M.A., Martynyuk T.V., Masenko V.P., Nakonechnikov S.N., Chazova I.E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/1681">https://cardiovascular.elpub.ru/jour/article/view/1681</self-uri><abstract><sec><title>Цель</title><p>Цель. Изучить взаимосвязь между выраженностью ремоделирования сердца и легочной артерии (ЛА) поданным эхокардиографии (ЭхоКГ) и уровнем натрийуретических пептидов (НУП), активацией ренин-ангиотензин-альдостероновой системы (РААС) у больных легочной гипертензией (ЛГ) различной этиологии.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В исследование были включены 111 больных ЛГ, в т.ч. 30 пациентов с идиопатичес-кой ЛГ (ИЛГ); 16 - с хронической тромбоэмболией ЛА (ТЭЛА); 19 - с системной склеродермией (СС); 15- с хронической обструктивной болезнью легких (ХОБЛ); 18 - с врожденными пороками сердца (ВПС); 13 - с резидуальной ЛГ(РЛГ), а также группа контроля - 21 доброволец. ЭхоКГ проводилась на приборе Vivid 7 (GE, США). У всех больных определяли в плазме крови уровни НУП - мозгового и предсердного, а также уровень ангиотензина II (AТ II) и активность ренина плазмы (АРП).</p></sec><sec><title>Результаты</title><p>Результаты. Выявлено достоверное повышение уровня НУП во всех группах больных, но наибольшее в группах ТЭЛА и ИЛГ. Активация РААС была обнаружена во всех группах за исключением ХОБЛ, максимальная в группе СС. Во всех группах больных отмечались расширение правых отделов сердца и ствола ЛА, снижение фракции выброса (ФВ) правого желудочка (ПЖ). Обращает на себя внимание наибольшая степень ремоделирования сердца в группах ИЛГ, ВПС и ТЭЛА, наименьшая у больных СС и ХОБЛ, что соответствует уровню СДЛА и ФВ ПЖ.</p></sec><sec><title>Заключение</title><p>Заключение. Процессы ремоделирования сердца были выявлены во всех группах больных ЛГ, однако наиболее значимые при ИЛГ, ВПС и ТЭЛА. Повышение НУП имело место у всех пациентов с ЛГ, наибольшее в группах ТЭЛА и ИЛГ. Выявлено достоверное повышение АРП и АТII у больных ИЛГ, ТЭЛА и СС, при этом при СС активация РААС была максимальной.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To study the associations between heart and pulmonary artery (PA) remodeling severity, according to echocardiography data, natriuretic peptide (NUP) levels, and renin-angiotensin-aldosterone system (RAAS) activation among patients with pulmonary hypertension (PH) of various etiology.</p></sec><sec><title>Material and methods</title><p>Material and methods. The study involved 111 patients with PH, including 30 subjects with idiopathic PH (IPH), 16with chronic PA thromboembolia (PATE), 19 with systemic scleroderma (SS), 15 with chronic obstructive pulmonary disease (COPD), 18 with congenital heart disease (CHD), 13 with residual PH (RPH), as well as 21 healthy controls. In all participants, echocardiography, EchoCG (Vivid 7, GE, USA) and measurement of plasma brain and atrial NUP, angiotensin II (AT II) and plasma renin activity (PRA) were performed.</p></sec><sec><title>Results</title><p>Results. Significant increase in NUP levels was observed in all subgroups, especially in those with PATE and IPH. RAAS activation was detected in all subgroups excluding those with COPD, being maximal in SS subgroup. In all subgroups, dilatation of right heart chambers and PA trunk, as well as decrease in right ventricular (RV) ejection fraction (EF), was observed. Heart remodeling severity was maximal in subjects with IPH, CHD, and PATE, and minimal - in those with SS and COPD, which is consistent with PA systolic pressure and RVEF levels in respective subgroups.</p></sec><sec><title>Conclusion</title><p>Conclusion. Heart remodeling was observed in all PH patients, being maximal in IPH, CHD, and PATE subgroups. Elevated NUP level, registered in all PH subjects, was highest in PATE and IPH subgroups. Significantly increased levels of PRA and AT II were observed in SS, IPH, and PATE individuals, with maximal RAAS activation among SS patients.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>легочная гипертензия</kwd><kwd>ремоделирование</kwd><kwd>натрийуретические пептиды</kwd><kwd>активация ренин-ангиотензин-альдостероновой системы</kwd></kwd-group><kwd-group xml:lang="en"><kwd>pulmonary hypertension</kwd><kwd>remodeling</kwd><kwd>natriuretic peptides</kwd><kwd>renin-angiotensin-aldosterone system activation</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Беленков Ю.Н., Чазова И. Е. Первичная легочная гипертензия. Москва "Нолидж" 1999.</mixed-citation><mixed-citation xml:lang="en">Беленков Ю.Н., Чазова И. Е. Первичная легочная гипертензия. Москва "Нолидж" 1999.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Диагностика и лечение легочной гипертензии. Российские рекомендации. ВНОК. Москва 2007.</mixed-citation><mixed-citation xml:lang="en">Диагностика и лечение легочной гипертензии. Российские рекомендации. ВНОК. Москва 2007.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Шиллер Н., Осипов М.А. Клиническая эхокардиография, второе издание. Москва "Практика" 2005.</mixed-citation><mixed-citation xml:lang="en">Шиллер Н., Осипов М.А. Клиническая эхокардиография, второе издание. Москва "Практика" 2005.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Vanderheyden M, Bartunek J, Goethals M. Brain and other natriuretic peptides: molecular aspects. Eur J Heart Failure 2004; 6: 261-8.</mixed-citation><mixed-citation xml:lang="en">Vanderheyden M, Bartunek J, Goethals M. Brain and other natriuretic peptides: molecular aspects. Eur J Heart Failure 2004; 6: 261-8.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Hall C. The value of natriuretic peptides for the management of heart failure: current state of play. Eur J Heart Fail 2001; 3: 395-7.</mixed-citation><mixed-citation xml:lang="en">Hall C. The value of natriuretic peptides for the management of heart failure: current state of play. Eur J Heart Fail 2001; 3: 395-7.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Постнов А.Ю., Постнов И.Ю., Волков В.Н., Батурова К.А. Содержание предсердного натрийуретического фактора в плазме крови больных с недостаточностью кровообращения. Кардиология 1987; 9: 109-10.</mixed-citation><mixed-citation xml:lang="en">Постнов А.Ю., Постнов И.Ю., Волков В.Н., Батурова К.А. Содержание предсердного натрийуретического фактора в плазме крови больных с недостаточностью кровообращения. Кардиология 1987; 9: 109-10.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Buckley M, Marcus N, Yacoub M, Singer D. Prolonged stability of brain natriuretic peptide: importance for-invasive assessment of cardiac function in clinical practice. Clin Sci 1998; 95: 235-9.</mixed-citation><mixed-citation xml:lang="en">Buckley M, Marcus N, Yacoub M, Singer D. Prolonged stability of brain natriuretic peptide: importance for-invasive assessment of cardiac function in clinical practice. Clin Sci 1998; 95: 235-9.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Burnett J, Kao P, Hu D, et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 1986; 231: 1145-7.</mixed-citation><mixed-citation xml:lang="en">Burnett J, Kao P, Hu D, et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 1986; 231: 1145-7.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Levin E, Gardner D, Samson W. Natriuretic peptides. N Engl J Med 1998; 339: 321-8.</mixed-citation><mixed-citation xml:lang="en">Levin E, Gardner D, Samson W. Natriuretic peptides. N Engl J Med 1998; 339: 321-8.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Yap LB, Mukerjee D, Timms PM, et al. Ashrafian H, Coghlan JG. Natriuretic peptides, respiratory disease, and the right heart. Chest 2004; 126(4): 1330-6.</mixed-citation><mixed-citation xml:lang="en">Yap LB, Mukerjee D, Timms PM, et al. Ashrafian H, Coghlan JG. Natriuretic peptides, respiratory disease, and the right heart. Chest 2004; 126(4): 1330-6.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Yap LB, Ashrafian H, Mukerjee D, et al. The natriuretic peptides and their role in disorders of right heart dysfunction and pulmonary hypertension. Clin Biochem 2004; 37(10): 847-56.</mixed-citation><mixed-citation xml:lang="en">Yap LB, Ashrafian H, Mukerjee D, et al. The natriuretic peptides and their role in disorders of right heart dysfunction and pulmonary hypertension. Clin Biochem 2004; 37(10): 847-56.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Pruszczyk P. N-terminal pro-brain natriuretic peptide as an indicator of right ventricular dysfunction. J Card Fail 2005; 11(5 Suppl): S65-9.</mixed-citation><mixed-citation xml:lang="en">Pruszczyk P. N-terminal pro-brain natriuretic peptide as an indicator of right ventricular dysfunction. J Card Fail 2005; 11(5 Suppl): S65-9.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Schoen SP, Zimmermann T, Kittner T, et al. NT-proBNP correlates with right heart haemodynamic parameters and volumes in patients with atrial septal defects. Eur J Heart Fail 2007; 9(6-7): 660-6. Epub 2007 Mar 7.</mixed-citation><mixed-citation xml:lang="en">Schoen SP, Zimmermann T, Kittner T, et al. NT-proBNP correlates with right heart haemodynamic parameters and volumes in patients with atrial septal defects. Eur J Heart Fail 2007; 9(6-7): 660-6. Epub 2007 Mar 7.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Kucher N, Printzen G, Goldhaber SZ. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation 2003;107: 2545-7.</mixed-citation><mixed-citation xml:lang="en">Kucher N, Printzen G, Goldhaber SZ. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation 2003;107: 2545-7.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Tulevski, II, Hirsch, A, Sanson, BJ, et al. Increased brain natriuretic peptide as a marker for right ventricular dysfunction in acute pulmonary embolism. Thromb Haemost 2001; 86: 1193-6.</mixed-citation><mixed-citation xml:lang="en">Tulevski, II, Hirsch, A, Sanson, BJ, et al. Increased brain natriuretic peptide as a marker for right ventricular dysfunction in acute pulmonary embolism. Thromb Haemost 2001; 86: 1193-6.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Mukerjee D, Yap LB, Holmes AM, et al. Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Respir Med 2003; 97(11): 1230-6.</mixed-citation><mixed-citation xml:lang="en">Mukerjee D, Yap LB, Holmes AM, et al. Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Respir Med 2003; 97(11): 1230-6.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Williams MH, Handler CE, Akram R, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2006; 27(12): 1485-94. Epub 2006 Apr 27. Comment in: Eur Heart J 2007; 28(1): 140-1; author reply 141.</mixed-citation><mixed-citation xml:lang="en">Williams MH, Handler CE, Akram R, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2006; 27(12): 1485-94. Epub 2006 Apr 27. Comment in: Eur Heart J 2007; 28(1): 140-1; author reply 141.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Бугримова М.А., Савина Н.М., Ваниева О.С, Сидоренко БА. Мозговой натрийуретический пептид как маркер и фактор прогноза при хронической сердечной недостаточности. Кардиология 2006; 1: 51-7.</mixed-citation><mixed-citation xml:lang="en">Бугримова М.А., Савина Н.М., Ваниева О.С, Сидоренко БА. Мозговой натрийуретический пептид как маркер и фактор прогноза при хронической сердечной недостаточности. Кардиология 2006; 1: 51-7.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Kazzam E, Caidahl K, Hedner T, Waldenstrцm A Functional explanation for increased atrial natriuretic peptide in systemic sclerosis. Clin Cardiol 1995; 18(11): 647-52.</mixed-citation><mixed-citation xml:lang="en">Kazzam E, Caidahl K, Hedner T, Waldenstrцm A Functional explanation for increased atrial natriuretic peptide in systemic sclerosis. Clin Cardiol 1995; 18(11): 647-52.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Kazzam E, Caidahl K, Hedner T, et al. Atrial natriuretic peptide and its relation to cardiac dimensions and function in patients with systemic sclerosis. Presse Med 1994; 23(12): 565-70.</mixed-citation><mixed-citation xml:lang="en">Kazzam E, Caidahl K, Hedner T, et al. Atrial natriuretic peptide and its relation to cardiac dimensions and function in patients with systemic sclerosis. Presse Med 1994; 23(12): 565-70.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Bolger AP, Sharma R, Li W, et al. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation 2002; 106(1): 92-9.</mixed-citation><mixed-citation xml:lang="en">Bolger AP, Sharma R, Li W, et al. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation 2002; 106(1): 92-9.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Garg R, Raman SV, Hoffman TM, et al. Serum Markers of Systemic Right Ventricular Function and Exercise Performance. Pediatr Cardiol 2008; 29(3): 641-8. Epub 2008 Jan 10.</mixed-citation><mixed-citation xml:lang="en">Garg R, Raman SV, Hoffman TM, et al. Serum Markers of Systemic Right Ventricular Function and Exercise Performance. Pediatr Cardiol 2008; 29(3): 641-8. Epub 2008 Jan 10.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Iivainen TE, Groundstroem KW, Lahtela JT, et al. Serum N-terminal atrial natriuretic peptide in adult patients late after surgical repair of atrial septal defect. Eur J Heart Fail 2000; 2(2): 161-5.</mixed-citation><mixed-citation xml:lang="en">Iivainen TE, Groundstroem KW, Lahtela JT, et al. Serum N-terminal atrial natriuretic peptide in adult patients late after surgical repair of atrial septal defect. Eur J Heart Fail 2000; 2(2): 161-5.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Richard C, Ricome JL, Lemoine F, et al. Value of captopril in the treatment of systemic arterial and pulmonary hypertension with increased plasma renin in scleroderma. Rev Med Interne 1983; 4(2): 125-9.</mixed-citation><mixed-citation xml:lang="en">Richard C, Ricome JL, Lemoine F, et al. Value of captopril in the treatment of systemic arterial and pulmonary hypertension with increased plasma renin in scleroderma. Rev Med Interne 1983; 4(2): 125-9.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Мартынюк ТВ.,Чазова И.Е., Масенко В.П.и др. Активность pенин-ангиотензин-альдостеpоновой системы и уpовень вазопpессина у пациентов с пеpвичной легочной гипеpтонией. Тер архив 1998; 70(4): 33-6.</mixed-citation><mixed-citation xml:lang="en">Мартынюк ТВ.,Чазова И.Е., Масенко В.П.и др. Активность pенин-ангиотензин-альдостеpоновой системы и уpовень вазопpессина у пациентов с пеpвичной легочной гипеpтонией. Тер архив 1998; 70(4): 33-6.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Zen GB. Hemodynamic changes and their relationship with the renin-angiotensin-aldosterone system in chronic obstructive pulmonary disease. Zhonghua Yi Xue Za Zhi 1989; 69(6): 311-4, 22.</mixed-citation><mixed-citation xml:lang="en">Zen GB. Hemodynamic changes and their relationship with the renin-angiotensin-aldosterone system in chronic obstructive pulmonary disease. Zhonghua Yi Xue Za Zhi 1989; 69(6): 311-4, 22.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Lin Y, Sun M, Ma Y RAAS changes due to dysfunction of pulmonary ventilation Zhonghua Jie He He Hu Xi Za Zhi 1996; 19(2): 84-7.</mixed-citation><mixed-citation xml:lang="en">Lin Y, Sun M, Ma Y RAAS changes due to dysfunction of pulmonary ventilation Zhonghua Jie He He Hu Xi Za Zhi 1996; 19(2): 84-7.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
